Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond.
Saghir Ali, Xiaochen Tian, Kathryn A. Cunningham, Jia Zhou
Journal of Medicinal Chemistry May 1, 2025 DOI: 10.1021/acs.jmedchem.5c01156 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Serotonin |
| Citations | 5 |
| Key findings | The 5-HT2A receptor is a promising target for developing psychedelic drugs and potential treatments for psychiatric disorders, though separating therapeutic from hallucinogenic effects remains a challenge. |
Abstract
Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond.
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cited by 3
- Discovery of Rapid-Acting, Orally Available Antidepressants by Activating TrkB Signaling. Journal of Medicinal Chemistry July 29, 2025
- Exploring Ayahuasca Multitarget Potential in Neuropsychiatric Disorders: Integrated Insights Towards Drug Discovery Current Pharmacology Reports August 24, 2026
- Trip killers: Addressing a critical knowledge gap in psychedelic research. Journal of Psychopharmacology May 1, 2026
Cites 16
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Crystal structure of an LSD-bound human serotonin receptor Cell January 26, 2017
- Structure-based discovery of nonhallucinogenic psychedelic analogs Science January 27, 2022
- Cessation and reduction in alcohol consumption and misuse after psychedelic use Journal of Psychopharmacology May 14, 2019
and 11 more in the library